Edwards Lifesciences Co. (NYSE:EW) is AIA Group Ltd's 10th Largest Position

AIA Group Ltd grew its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 28.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 601,745 shares of the medical research company's stock after acquiring an additional 134,452 shares during the quarter. Edwards Lifesciences accounts for 1.9% of AIA Group Ltd's holdings, making the stock its 10th biggest position. AIA Group Ltd owned 0.10% of Edwards Lifesciences worth $45,883,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Moneta Group Investment Advisors LLC increased its holdings in shares of Edwards Lifesciences by 104,971.3% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company's stock worth $1,148,938,000 after acquiring an additional 15,384,593 shares in the last quarter. Norges Bank bought a new position in shares of Edwards Lifesciences during the fourth quarter worth about $658,390,000. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST lifted its stake in Edwards Lifesciences by 440.0% in the 3rd quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 3,510,000 shares of the medical research company's stock valued at $243,173,000 after acquiring an additional 2,860,000 shares in the last quarter. AustralianSuper Pty Ltd acquired a new position in Edwards Lifesciences during the 4th quarter worth approximately $168,519,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its stake in shares of Edwards Lifesciences by 655.9% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,325,457 shares of the medical research company's stock worth $173,502,000 after acquiring an additional 2,017,801 shares in the last quarter. Institutional investors own 79.46% of the company's stock.

Insider Buying and Selling

In other news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total value of $567,993.95. Following the transaction, the chief financial officer now owns 19,248 shares in the company, valued at approximately $1,506,925.92. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CFO Scott B. Ullem sold 7,255 shares of the company's stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at approximately $1,506,925.92. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Catherine M. Szyman sold 27,000 shares of the firm's stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the sale, the vice president now owns 34,814 shares in the company, valued at approximately $2,980,774.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 194,004 shares of company stock worth $17,166,254. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Stock Performance

NYSE EW traded down $0.79 during trading on Thursday, reaching $86.45. The company's stock had a trading volume of 3,121,938 shares, compared to its average volume of 3,865,237. The firm has a market capitalization of $52.04 billion, a price-to-earnings ratio of 37.59, a price-to-earnings-growth ratio of 4.46 and a beta of 1.05. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. The firm has a 50 day moving average price of $90.14 and a 200 day moving average price of $78.19.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, hitting analysts' consensus estimates of $0.64. The company had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. Edwards Lifesciences's revenue was up 13.3% on a year-over-year basis. During the same quarter last year, the business earned $0.64 earnings per share. As a group, equities analysts anticipate that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. Evercore ISI boosted their price objective on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the stock an "in-line" rating in a research report on Thursday, April 4th. StockNews.com downgraded Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Wednesday, March 20th. Citigroup lifted their price objective on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the company a "neutral" rating in a research report on Wednesday, April 3rd. OTR Global raised Edwards Lifesciences from a "mixed" rating to a "positive" rating in a research report on Tuesday, March 26th. Finally, Truist Financial upped their price objective on Edwards Lifesciences from $78.00 to $84.00 and gave the company a "buy" rating in a research note on Friday, December 22nd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $91.73.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.